{"disease":{"id":"japanese-encephalitis","name":"Japanese encephalitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Japanese encephalitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Japanese encephalitis (JE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Japanese encephalitis (JE) booster","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06372665","title":"Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization","phase":"","overall_status":"COMPLETED","enrollment_count":15357,"lead_sponsor_name":"Liaoning Chengda Biotechnology CO., LTD","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT04223037","title":"Purified Inactivated Japanese Encephalitis Vaccine","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04817917","title":"Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":712,"lead_sponsor_name":"Zhejiang Provincial Center for Disease Control and Prevention","has_results":false},{"nct_id":"NCT03282370","title":"Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":655,"lead_sponsor_name":"National Institute of Hygiene and Epidemiology, Vietnam","has_results":false},{"nct_id":"NCT06825312","title":"Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Liaoning Chengda Biotechnology CO., LTD","has_results":false},{"nct_id":"NCT01001988","title":"Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT01190228","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT06331702","title":"Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Liaoning Chengda Biotechnology CO., LTD","has_results":false},{"nct_id":"NCT06680128","title":"A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":402,"lead_sponsor_name":"SK Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT00463476","title":"Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"PATH","has_results":true},{"nct_id":"NCT00463684","title":"Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":278,"lead_sponsor_name":"PATH","has_results":true},{"nct_id":"NCT06678373","title":"Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Liaoning Chengda Biotechnology CO., LTD","has_results":false},{"nct_id":"NCT03204227","title":"Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"National Institute of Hygiene and Epidemiology, Vietnam","has_results":false},{"nct_id":"NCT01900444","title":"Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT02933710","title":"Postmarketing Surveillance Study for IMOJEV® in Republic of Korea","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03920111","title":"Flavivirus Cross-priming Potential of IMOJEV","phase":"NA","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"University of Liverpool","has_results":true}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}